Additionally, the 36-month beta value for BJDX is 0.72. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for BJDX is 16.47M and currently, short sellers hold a 0.97% ratio of that float. The average trading volume of BJDX on November 04, 2024 was 3.21M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BJDX) stock’s latest price update
Bluejay Diagnostics Inc (NASDAQ: BJDX)’s stock price has gone decline by -6.08 in comparison to its previous close of 0.08, however, the company has experienced a -25.59% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-06-28 that ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company. The base offering consisted of 5,368,098 Common Units or Prefunded Units, each Unit consisting of one share of the Company’s common stock (“Common Stock”) or one pre-funded warrant to purchase one share of Common Stock (each, a “Prefunded Warrant”), two Class C warrants each to purchase one share of our common stock (each, a “Class C Warrant”) and one Class D Warrant to purchase such number of shares of common stock as determined in the Class D Warrant (each, a “Class D Warrant” and together with the Class C Warrants, the “Common Warrants”). The purchase price of each Common Unit is $1.63, and the purchase price of each Prefunded Unit is $1.6299 (which is equal to the public offering price per Common Unit minus $0.0001). The Prefunded Warrants will be immediately exercisable and may be exercised at any time until all the Prefunded Warrants are exercised in full.
BJDX’s Market Performance
Bluejay Diagnostics Inc (BJDX) has seen a -25.59% fall in stock performance for the week, with a -41.28% decline in the past month and a -81.73% plunge in the past quarter. The volatility ratio for the week is 10.55%, and the volatility levels for the past 30 days are at 13.56% for BJDX. The simple moving average for the last 20 days is -23.80% for BJDX’s stock, with a simple moving average of -97.37% for the last 200 days.
BJDX Trading at -40.96% from the 50-Day Moving Average
After a stumble in the market that brought BJDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.75% of loss for the given period.
Volatility was left at 13.56%, however, over the last 30 days, the volatility rate increased by 10.55%, as shares sank -39.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.64% lower at present.
During the last 5 trading sessions, BJDX fell by -26.35%, which changed the moving average for the period of 200-days by -98.90% in comparison to the 20-day moving average, which settled at $0.1034. In addition, Bluejay Diagnostics Inc saw -99.19% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BJDX starting from Dey Svetlana, who purchase 500 shares at the price of $3.07 back on Dec 13 ’23. After this action, Dey Svetlana now owns 1,500 shares of Bluejay Diagnostics Inc, valued at $1,535 using the latest closing price.
Dey Indranil, the President and CEO of Bluejay Diagnostics Inc, purchase 500 shares at $3.27 during a trade that took place back on Dec 13 ’23, which means that Dey Indranil is holding 28,526 shares at $1,635 based on the most recent closing price.
Stock Fundamentals for BJDX
Current profitability levels for the company are sitting at:
- -6.25 for the present operating margin
- 0.7 for the gross margin
The net margin for Bluejay Diagnostics Inc stands at -6.49. The total capital return value is set at -1.03. Equity return is now at value -125.25, with -97.27 for asset returns.
Based on Bluejay Diagnostics Inc (BJDX), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -18.65. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -9.77.
Currently, EBITDA for the company is -9.53 million with net debt to EBITDA at 0.88. When we switch over and look at the enterprise to sales, we see a ratio of -4.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.38.
Conclusion
In conclusion, Bluejay Diagnostics Inc (BJDX) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
